These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37024504)

  • 1. Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy.
    Yi J; Tavana O; Li H; Wang D; Baer RJ; Gu W
    Nat Commun; 2023 Apr; 14(1):1941. PubMed ID: 37024504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1.
    Kuang Z; Liu X; Zhang N; Dong J; Sun C; Yin M; Wang Y; Liu L; Xiao D; Zhou X; Feng Y; Song D; Deng H
    Cell Death Differ; 2023 Oct; 30(10):2249-2264. PubMed ID: 37670038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.
    Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA
    Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A role of HAUSP in tumor suppression in a human colon carcinoma xenograft model.
    Becker K; Marchenko ND; Palacios G; Moll UM
    Cell Cycle; 2008 May; 7(9):1205-13. PubMed ID: 18418047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.
    Wang W; Takimoto R; Rastinejad F; El-Deiry WS
    Mol Cell Biol; 2003 Mar; 23(6):2171-81. PubMed ID: 12612087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276.
    Li R; Zatloukalova P; Muller P; Gil-Mir M; Kote S; Wilkinson S; Kemp AJ; Hernychova L; Wang Y; Ball KL; Tao K; Hupp T; Vojtesek B
    Cell Mol Biol Lett; 2020; 25():41. PubMed ID: 32874188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage.
    Khoronenkova SV; Dianova II; Ternette N; Kessler BM; Parsons JL; Dianov GL
    Mol Cell; 2012 Mar; 45(6):801-13. PubMed ID: 22361354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
    Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
    Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HAUSP-nucleolin interaction is regulated by p53-Mdm2 complex in response to DNA damage response.
    Lim KH; Park JJ; Gu BH; Kim JO; Park SG; Baek KH
    Sci Rep; 2015 Aug; 5():12793. PubMed ID: 26238070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of the USP2-E2F4 axis inhibits autophagic machinery essential for zinc homeostasis in cancer progression.
    Xiao W; Wang J; Wang X; Cai S; Guo Y; Ye L; Li D; Hu A; Jin S; Yuan B; Zhou Y; Li Q; Tong Q; Zheng L
    Autophagy; 2022 Nov; 18(11):2615-2635. PubMed ID: 35253629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of HAUSP in vivo modulates p53 function.
    Kon N; Kobayashi Y; Li M; Brooks CL; Ludwig T; Gu W
    Oncogene; 2010 Mar; 29(9):1270-9. PubMed ID: 19946331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
    Gupta A; Shah K; Oza MJ; Behl T
    Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the MDM2-p53 interaction for cancer therapy.
    Shangary S; Wang S
    Clin Cancer Res; 2008 Sep; 14(17):5318-24. PubMed ID: 18765522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STIP is a critical nuclear scaffolding protein linking USP7 to p53-Mdm2 pathway regulation.
    Ye M; Tang Y; Tang S; Liu J; Wu K; Yao S; Sun Y; Zhou L; Deng T; Chen Y; Huang C; Tan W
    Oncotarget; 2015 Oct; 6(33):34718-31. PubMed ID: 26460617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. USP49-Mediated Histone H2B Deubiquitination Regulates HCT116 Cell Proliferation through MDM2-p53 Axis.
    Shi L; Shen X; Shen Y
    Mol Cell Biol; 2022 Mar; 42(3):e0043421. PubMed ID: 35072515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics in the p53-Mdm2 ubiquitination pathway.
    Brooks CL; Gu W
    Cell Cycle; 2004 Jul; 3(7):895-9. PubMed ID: 15254415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation.
    Mungamuri SK; Qiao RF; Yao S; Manfredi JJ; Gu W; Aaronson SA
    Cell Rep; 2016 Mar; 14(11):2528-37. PubMed ID: 26971997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. F-box protein FBXO31 modulates apoptosis and epithelial-mesenchymal transition of cervical cancer via inactivation of the PI3K/AKT-mediated MDM2/p53 axis.
    Liu K; Xue B; Bai G; Zhang W
    Life Sci; 2020 Oct; 259():118277. PubMed ID: 32800832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins.
    Lee MH; Lozano G
    Semin Cancer Biol; 2006 Jun; 16(3):225-34. PubMed ID: 16697215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.